Orchestrating the immune Response
TO Defeat Cancer & Infectious Diseases
Engineering precision immunity
Elicio Therapeutics is re-engineering the body’s immune response to defeat cancer and infectious diseases with potent lymph node targeted immunotherapies and vaccines. Elicio’s Amphiphile platform combines expertise in materials science and immunology to develop novel immunotherapies and vaccines, including cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.
Lymph nodes:
where the immune response is orchestrated
Elicio has demonstrated preclinically that Amphiphiles target and concentrate an array of different immunogens in the lymph nodes, resulting in tumor or pathogen targeted immunity, including potent T cell and humoral responses. Elicio’s lead Amphiphile program for KRAS-driven cancers will enter initial patient studies in early 2021.
NEXT-GENERATION IMMUNO-ONCOLOGY PLATFORM
Our programs
Elicio will begin multiple Phase 1/2 studies for ELI-002 in 2021. This program consists of an Amphiphile vaccine combined with Elicio’s universal AMP CpG adjuvant (ELI-004) with the potential to elicit powerful immune responses against the seven key KRAS mutations, found in 25% of all solid tumors, including 90% of pancreatic cancers, and 40% of colorectal cancers.
Latest News
May 16, 2022 ||
Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo® (cemiplimab) in KRAS-Driven Tumors
The ELI-002 and Libtayo® combination will be studied in KRAS-driven tumors including Stage III and IV non-small cell lung cancer (NSCLC), Stage IV colorectal cancer (CRC) and unresectable, locally advanced or oligometastatic pancreatic ductal adenocarcinoma (PDAC) » Read more
May 12, 2022 ||
Elicio Therapeutics Announces Appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and Promotion of Dr. Peter DeMuth to Chief Scientific Officer
BOSTON, May 12, 2022 – Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, today announced the appointment of Joy Seymour as Vice President, Head of Regulatory Affairs and the promotion of Dr. Peter DeMuth to Chief Scientific Officer. Ms. Seymour will oversee the […] » Read more
Orchestrating the immune system for precision immunity — Download this article to see how Elicio’s lymph node-targeting Amphiphile technology delivers potent T cell activation and boosts the effects of engineered cell therapies.
A Lymph Node Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2 Download this presentation